Kinetic Concepts, Inc. 

(Public, NYSE:KCI)   Watch this stock   
Find more results for KCI
Nov 9, 2009
2009 Analyst Day - Webcast
Oct 21, 2009
Q3 2009 Earnings Conference Call - Webcast
Oct 21, 2009
Q3 2009 Earnings Release
Sep 10, 2009
Thomas Weisel Partners Healthcare Conference - Webcast
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 12.80% 9.26%
Operating margin 22.65% 18.56%
EBITD margin - 25.77%
Return on average assets 8.69% 8.56%
Return on average equity 24.48% 23.37%
Employees 6,900 -

Address

8023 Vantage Drive
San Antonio, TX 78230
United States - Map
+1-210-5249000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Kinetic Concepts, Inc. discussed on blogs

Ranking 700+ Mid-Cap Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 8 hours ago

Kinetic Concepts, Inc. discussions

  View all discussions »

Description

Kinetic Concepts, Inc. (KCI) is a global medical technology company that manages advanced wound care, regenerative medicine and therapeutic surfaces. The Company’s advanced wound care systems, regenerative medicine products and therapeutic support systems for five principal clinical applications: advanced wound healing and tissue repair, pulmonary complications in the intensive care unit (ICU), regenerative medicine, bariatric care and wound treatment and prevention. Its Therapeutic Support Systems (TSS) business includes hospital beds, mattress replacement systems and overlays, which are designed for pulmonary complications associated with immobility, to reduce or treat skin breakdown and assist caregivers in the safe and dignified handling of patients of size. On May 27, 2008, the Company acquired LifeCell Corporation (LifeCell). LifeCell develops, processes and markets biological soft tissue repair products made from both allograft and xenograft tissue.

Officers and directors

Ronald W. Dollens
Chairman of the Board
Age: 62
Bio & Compensation - Reuters
Catherine M. Burzik
President, Chief Executive Officer, Director
Age: 58
Bio & Compensation - Reuters
Martin J. Landon
Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation - Reuters
Lynne D. Sly
Global President - Therapeutic Support Systems
Age: 48
Bio & Compensation - Reuters
T. L.V. Kumar
President, Europe, Middle East & Africa (EMEA)
Age: 54
Bio & Compensation - Reuters
Patrick Loh
President, Asia Pacific
Age: 41
Bio & Compensation - Reuters
Lisa N. Colleran
President - LifeCell Corporation
Age: 51
Bio & Compensation - Reuters
Michael Genau
Global President of Wound Therapy
Bio & Compensation - Reuters
Stephen D. Seidel
Executive Vice President, Chief Administrative Officer, General Counsel
Age: 52
Bio & Compensation - Reuters
Todd M. Fruchterman M.D., Ph.D.
Senior Vice President - Research and Development, Chief Technology Officer, Chief Medical Officer
Age: 39
Bio & Compensation - Reuters